- RecruitingPHASE3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
This study is for people with advanced bowel cancer that has spread and has a specific gene change called KRAS p.G12C. It compares a new combination of treatments to standard treatment to see if it can better stop the cancer from growing.
For: Metastatic Colorectal CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
This study compares two treatments for a specific type of advanced lung cancer. It looks at how well a treatment combining sotorasib with chemotherapy works against one combining pembrolizumab with chemotherapy, focusing on extending life and preventing cancer growth.
For: Non-Small Cell Lung Cancer (NSCLC)United States · Argentina · Australia - Active not recruitingPHASE1
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
This study is looking into new ways to treat advanced cancers that have a specific genetic change called KRAS p.G12C. It's testing a drug called sotorasib, either by itself or with other treatments, to see how safe and effective they are for adults.
For: Advanced Solid Tumors · Kirsten Rat Sarcoma (KRAS) pG12C MutationUnited States · Australia · Austria - RecruitingPHASE2
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
This study looks at continuing treatment with sotorasib, sometimes with a drug called panitumumab, for people with advanced cancers that have a specific genetic change (KRAS p.G12C). It checks how safe the treatments are and if they're well-tolerated.
For: Advanced Solid TumorsUnited States · Australia · France - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at a new drug, divarasib, for advanced lung cancer with a specific genetic change (KRAS G12C). It compares divarasib to existing treatments, sotorasib or adagrasib, to see how well they work and if they are safe.
For: Non-Small Cell Lung Cancer · KRAS G12C Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE1
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
This study, called MTAPESTRY 104, is testing a new drug called Anvumetostat, alone or with other treatments, for advanced lung cancers that have a specific genetic change (MTAP-deletion). It aims to find the safest and most effective dose.
For: Thoracic Tumors · Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
This study is testing a new medicine called sotorasib for people with specific advanced cancers carrying a KRAS p.G12C gene change. Researchers want to see if it's safe, how much to give, and if it helps shrink tumours. It's an early-stage trial looking for better cancer treatments.
For: KRAS p.G12C Mutant Advanced Solid TumorsUnited States · Australia · Austria - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Sotorasib (AMG 510) Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and Sotorasib (AMG 510) Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreaK 100)
This study is testing a new medicine, Sotorasib, for people with advanced cancers that have a specific genetic change called KRAS p.G12C. Researchers want to see if it's safe and effective, both on its own and when combined with other treatments.
For: KRAS p.G12C Mutant Advanced Solid TumorsSpain · France · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects with Stage IV NSCLC whose Tumors Harbor a KRASG12C Mutation in Need of First-Line Treatment (CodeBreak 201)
This study is looking at a new medicine called sotorasib for people with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C mutation). The main goal is to see how many patients' tumors shrink or disappear.
For: Non-small cell lung cancer (NSCLC)Belgium · Spain · Sweden